Article
The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.
Cancer investigation - 1 Aug 2013
Chen Bei, Xiao Feng, Li Baofeng, Xie Bo, Zhou Juan, Zheng Jihua, Zhang Weimin
Abstract excerpt
OBJECTIVE: Except for EGFR gene mutation, there is still lack of predictive factors for gefitinib activity as the second-line treatments for advanced NSCLC with wild-type (WT) EGFR or patients with mutant EGFR but showed poor response. Our purpose was to assess the predictive value of epithelial-mesenchymal transition (EMT) and IGF-1R for gefitinib efficacy as the second-line treatment for NSCLC. METHODS: 53...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.